Treatment of influenza with baloxavir was associated with reduced absenteeism compared with oseltamivir in a patient-generated health data study

Alejandra Benitez,¹ Hao Xu,² Devika Chawla,¹ Vincent Ukachukwu³

¹Genentech, Inc., South San Francisco, USA; ²F. Hoffmann-La Roche Ltd, Mississauga, Canada; ³Roche Products Ltd, Welwyn Garden City, UK



Impact of influenza on workplace absenteeism Over 80% of participants with ILI reported missing ≥1 day of work



Association between antiviral use and workplace absenteeism Use of baloxavir was associated with lower odds of absenteeism compared with oseltamivir

INTRODUCTION

RESULTS

Characteristics, n (%)

Age (years)

American region

OTC medication

CDC risk factors


Antiviral use in

use

- Lost productivity from workplace absenteeism is a significant component of the economic burden of influenza-like illness (ILI).1
- In clinical trials, baloxavir, an oral single-dose influenza antiviral, reduced viral shedding more rapidly than oseltamivir in otherwise-healthy adults and adolescents with influenza.2
- Baloxavir was also shown to be superior to oseltamivir in improving symptoms in high-risk patients with influenza B;3 therefore, it is possible that baloxavir may lead to a shortening of workplace absenteeism.
- Here, we examined baloxavir real-world outcomes using patient-generated health data to investigate the association between antiviral use and workplace absenteeism.

METHODS

- Patient-generated health data from a participatory ILI surveillance program (ISP) was used to identify participants who self-reported ILI using the online Evidation platform during the 2019-2020 influenza season in the USA (Figure 1).
- Participants who met the following criteria were eligible for inclusion in the study:
- Sought medical attention
- Actively attended work (excluded those retired or sick on weekends)
- Received treatment with baloxavir or oseltamivir
- An ordinal logistic regression was conducted to estimate the odds of missing work due to ILI, while adjusting for over-the-counter (OTC) medication use. age, number of symptoms, US region, and comorbidities.



- Of 3.658 eligible participants. 3.285 (89.8%) were prescribed oseltamivir and 373 (10.2%) were prescribed baloxavir (Table). Most participants (81.7%) reported missing ≥1 day of work.
- Fewer participants who received baloxavir treatment reported missing ≥4 days of work compared with those who received oseltamivir treatment (23.6% vs 29.3%, respectively; p=0.0004; Figure 2).
- Baloxavir use was associated with lower odds of absenteeism compared with oseltamivir (odds ratio [OR]: 0.748, 95% confidence interval [CI]: 0.616, 0.907) when controlling for other measured confounders.

Oseltamivir

(n=3.285)

2,969 (90.4)

316 (9.6)

546 (16.6)

1,617 (49.2)

682 (20.8)

440 (13.4)

874 (26.6)

2,411 (73.4)

1,548 (47.1)

1,737 (52.9)

1.464 (44.6)

1,014 (30.8)

807 (24.5)

442 (13.5)

964 (29.3)

1,879 (57.2)

6 [4.7]

A higher number of symptoms (OR: 2,922, 95% CI: 2,454, 3,481), older age (OR: 1,425, 95% CI: 1,162, 1,747), and use of OTC medication (OR: 1.242, 95% CI: 1.086, 1.420) were associated with higher odds of absenteeism when controlling for other measured confounders.

p value

0.116

0.020

0.982

0.001

0.657

< 0.001

Table. Demographics and baseline characteristics

18 - 49

South

West

No

Yes

Yes

No

1 - 3

4-5

6-7

Mean

[IQR]

Missing

0

1

Midwest

Northeast

50+

Baloxavir

(n=373)

347 (93.0)

26 (7.0)

49 (13.1)

215 (57.6)

64 (17.2)

45 (12.1)

100 (26.8)

273 (73.2)

210 (56.3)

163 (43.7)

175 (46.9)

108 (28.9)

90 (24.1)


108 (29.0)

93 (24.9)

5 [3.7]

172 (46.1)

Figure 2. Days of missed work, by antiviral treatment



References

- 1. Tsuzuki S. Yoshihara K. BMC Public Health 2020;20(1):568
- 2. Hayden FG, et al. N Engl J Med 2018;379: 913-23.
- 3. Ison MG, et al. Lancet Infect Dis 2020:20(10):1204-14.

*DC is now an employee of Myriad Genetics, Inc. [†]HX is now an employee of AstraZeneca Canada

LIMITATIONS

- The association between the timing of antiviral use and absenteeism could not be adequately assessed due to missing data (24.5%).
- While most cases of ILI in our study population were reported before March 2020, care-seeking behaviour may have been affected by the COVID-19 pandemic.
- A low proportion of individuals in this cohort received baloxavir since it more recently entered the market: additionally, due to the observational nature of the study, the sample may not be representative of those who are prescribed baloxavir or oseltamivir.

CONCLUSIONS

- Treatment of patients with ILI with a single dose of baloxavir was associated with a shortening in workplace absenteeism compared with oseltamivir after adjusting for measured confounders.
- This study provides useful insight into factors associated with ILI-related workplace absenteeism and the potential real-world utility of baloxavir.

Disclosures

AB is an employee of Genentech, Inc.; VU is an employee of Roche Products Ltd. When this study was conducted, DC was an employee of Genentech, Inc.* and HX was an employee of E Hoffmann-La Roche Ltd †

Acknowledgements

Third-party medical writing assistance, under the direction of the authors, was provided by Ed Harratt of Ashfield MedComms, an Inizio company, and funded by F. Hoffmann-La Roche Ltd.

Presented at IDWeek 2022, Abstract #1471,